Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Tipranavir/Ritonavir on Efavirenz PK in Healthy Volunteers
NCT02253823Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2001
- Primary completion
- Mar 2002
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of tipranavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum measured concentration of the analyte in plasma, Area under the plasma concentration time curve from 0-12 hours and 3 more. Started Dec 2001; status: completed.
02
Drugs
tipranavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02253823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02253823.